JP2022514739A5 - - Google Patents

Info

Publication number
JP2022514739A5
JP2022514739A5 JP2021534981A JP2021534981A JP2022514739A5 JP 2022514739 A5 JP2022514739 A5 JP 2022514739A5 JP 2021534981 A JP2021534981 A JP 2021534981A JP 2021534981 A JP2021534981 A JP 2021534981A JP 2022514739 A5 JP2022514739 A5 JP 2022514739A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
composition according
integer
formula
aging composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021534981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514739A (ja
JP7641897B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/066553 external-priority patent/WO2020131704A1/en
Publication of JP2022514739A publication Critical patent/JP2022514739A/ja
Publication of JP2022514739A5 publication Critical patent/JP2022514739A5/ja
Application granted granted Critical
Publication of JP7641897B2 publication Critical patent/JP7641897B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021534981A 2018-12-17 2019-12-16 抗加齢のための三剤組合せ療法 Active JP7641897B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862780488P 2018-12-17 2018-12-17
US62/780,488 2018-12-17
US201962804411P 2019-02-12 2019-02-12
US62/804,411 2019-02-12
US201962834794P 2019-04-16 2019-04-16
US62/834,794 2019-04-16
PCT/US2019/066553 WO2020131704A1 (en) 2018-12-17 2019-12-16 Triple combination therapies for anti-aging

Publications (3)

Publication Number Publication Date
JP2022514739A JP2022514739A (ja) 2022-02-15
JP2022514739A5 true JP2022514739A5 (enExample) 2022-12-26
JP7641897B2 JP7641897B2 (ja) 2025-03-07

Family

ID=71102298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021534981A Active JP7641897B2 (ja) 2018-12-17 2019-12-16 抗加齢のための三剤組合せ療法

Country Status (20)

Country Link
US (2) US11918597B2 (enExample)
EP (1) EP3897659A4 (enExample)
JP (1) JP7641897B2 (enExample)
KR (1) KR20210104830A (enExample)
CN (1) CN113453690A (enExample)
AU (1) AU2019402099B2 (enExample)
BR (1) BR112021011964A2 (enExample)
CA (1) CA3123850A1 (enExample)
CL (1) CL2021001617A1 (enExample)
CO (1) CO2021009008A2 (enExample)
CR (1) CR20210351A (enExample)
DO (1) DOP2021000123A (enExample)
EC (1) ECSP21052757A (enExample)
IL (1) IL284059B2 (enExample)
MX (1) MX2021007347A (enExample)
PE (1) PE20220499A1 (enExample)
PH (1) PH12021551435A1 (enExample)
SG (1) SG11202106532WA (enExample)
WO (1) WO2020131704A1 (enExample)
ZA (1) ZA202104254B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210072026A (ko) 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
EP3923941B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and ribociclib
BR112022022185A2 (pt) * 2020-05-13 2022-12-13 Lunella Biotech Inc Derivados de miristoíla de 9-amino-doxiciclina para alvejar células-tronco cancerígenas e prevenir metástase
WO2025114970A1 (en) * 2023-11-30 2025-06-05 Lunella Biotech, Inc. Senolytic compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
CN1837229A (zh) * 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
US7282225B1 (en) * 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
WO2012112945A1 (en) * 2011-02-18 2012-08-23 The Trustees Of Columbia University In The City Of New York Use of matrix metalloproteinase inhibitors to treat tuberculosis
WO2013024467A2 (en) 2011-08-18 2013-02-21 Ecole Polytechnique Federale De Lausanne (Epfl) Mitochondrial ribosomal proteins as aging regulators
US9775855B2 (en) * 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
GB201217310D0 (en) * 2012-09-27 2012-11-14 C10 Pharma As Compounds
CN103536530A (zh) * 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
US11311501B2 (en) * 2017-03-15 2022-04-26 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018193116A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Azithromycin derivatives containing a phosphonium ion as anticancer agents
US11197872B2 (en) 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
PH12019502594A1 (en) * 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11883497B2 (en) * 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
KR20210072026A (ko) * 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
AU2019403048B2 (en) * 2018-12-17 2025-01-23 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells

Similar Documents

Publication Publication Date Title
JP2022514739A5 (enExample)
ES3013603T3 (en) A composition for weight loss or weight management comprising beta-hydroxybutyrate and cannabidiol
JP6141929B2 (ja) アントシアニジンを含む組成物及び使用方法
AU2001253919B2 (en) Administration of a thiol-based chemoprotectant compound
AU2023222925B2 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
WO2010129337A3 (en) New oral formulations for tetrapyrrole derivatives
JP2021008509A (ja) トコトリエノールの経粘膜送達
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
US11896598B2 (en) Appetite suppressant compositions and methods thereof
US20250099498A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
Kessler et al. Hearing loss during chemotherapy: prevalence, mechanisms, and protection
EP3461479B1 (en) Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
CZ285000B6 (cs) Antiemetické kompozice
WO2021099453A1 (fr) Extrait liquide aqueux de spiruline pour la prévention et/ou le traitement des neuropathies périphériques chimio-induites et leurs symptômes, composition et utilisation correspondantes
US20170157169A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation
CA3074541C (en) Appetite suppressant compositions and methods thereof
JP6322575B2 (ja) 脂質マイクロカプセルのデリバリービヒクルを含む局所用製剤およびその使用
Vadivelan et al. The ‘golden hour’in paraquat poisoning
RU2021121094A (ru) Тройная комбинированная терапия против старения
ES2207166T3 (es) Composicion fungicida que comprende una benzoilfenilurea.
RU2019110755A (ru) Сублингвальное или буккальное введение dim для лечения заболеваний кожи
EP1965791B1 (de) Neue kompositionen gegen alkyl-acyl-gpc, seine derivate und produkte
RU95107140A (ru) Способ лечения генерализованной формы демодекоза собак, осложненной стафилококкозом и грибковой инфекцией
CA3167614C (en) Nutritional compositions and methods containing a lignan and a methyl donor
CA2958169A1 (en) Strontium based compositions and formulations for pain, pruritus, and inflammation